CTOs on the Move


 
NatureWorks LLC is a Minnetonka, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Expansion Therapeutics

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

Immusoft

Immusoft Corporation (immusoft.com) is a pre-clinical gene therapy company based in Seattle, Wash. Its mission is to treat diseases using its breakthrough technology platform called Immune System Programming.

Biolex Therapeutics

Biolex Therapeutics is a Pittsboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clade Therapeutics

Clade Therapeutics is a well-funded cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located in the heart of Cambridge was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.